In this next segment, I take Hans up on his offer to

New Post Public Reply Private Reply Replies (0) Message Board
steelerfan7

In this next segment, I take Hans up on his offer to examine one of my patients. Read what happens next!

Countdown: 5 days until the release of  End Back Pain Forever! #endbackpain

Chapter 2

You Are Not Alone: The Back Pain Epidemic (Part 5)

Dr. Kraus and I met a week later at Lenox Hill. I had chosen a patient whom I shall call Beth. She was a forty-five year-old woman so defeated by pain after three unsuccessful spinal operations that she could no longer hold a job. Her life had revolved around her work, which was at the core of her sense of self. She was devastated. No one had found a truly successful treatment for her, and I did not believe that anyone could. She was on high doses of morphine, 60 milligrams orally five to six times a day, to relieve her pain.

After reviewing her case history, Dr. Kraus gave her a comprehensive and thoughtful mental and physical examination. Starting with her neck, he used his fingertips to palpate her muscles to distinguish between those that were supple and pain free and those that were stiff and painful. He found five pairs of painful muscles on both sides of the lower back, buttocks, and thighs.  “If these muscles are treated properly,” he told me, “it should reduce or eliminate her pain.”

I couldn’t believe that this would be the case. Her diagnosis was arachnoiditis, inflammation of the deep layer of the membranous tissue surrounding the spinal cord. In Beth’s case, it was caused by the dye that radiologists use to outline the spinal cord when performing a special X-ray called a myelogram. The oil-based dye used in the past sometimes irritated the tissue, producing scarring that could squeeze nerves and bring about pain in the back and legs. (Today a nonirritating water-based dye is used instead.) I had done my best to help her live with the pain in my pain management program. Even though she reported a 50 percent improvement, she was still taking large doses of morphine and couldn’t return to work.

Beth and I had nothing to lose by trying. She demonstrated all of the reasons for muscle pain that I will explore with you as you get further into End Back Pain Forever. Beth was tense, weak, and stiff (deconditioned). She had areas of persistent painful contractions, or spasming, and tender spots in her muscles that Dr. Kraus knew from experience would respond to injections of lidocaine, a numbing solution. Beth would need prescribed exercises, but because her pain was so severe that all movement hurt, Dr. Kraus decided to start her treatment with injections into the identified painful muscles and then quickly add exercises.

The injection technique – different from the trigger point injections popular among other pain physicians – concentrated on the areas where the muscles attached to the tendon and the bone, in contrast to the tender nodules in the muscle tissue. (More on this later.) Only one muscle could be treated per day, and each injected muscle received three days of a special physical therapy protocol to restore its flexibility.

Four weeks later, the patient that I had considered “impossible to treat” returned to work free of pain. This was the most important medial awakening in my career.

Beth’s arachnoiditis was a bona fide diagnosis. I had seen her CT scan following a myelogram. In fact, it had shown severe arachnoiditis. But her pain at that moment came from her muscles, not from her arachnoiditis. If we had not examined and found the painful muscles, she never could have been treated properly for the pain, and she would have been on the same medication, getting marginal results, for the rest of her life. It forced me to wonder how many other patients of mine were suffering needlessly because I had reflexively attributed their pain to their existing diagnoses, and whether they too were not receiving the proper treatment that could eliminate or diminish their suffering.

The successful resolution of Beth’s case was such a revelation that I asked Dr. Kraus if he would  be good enough to come to the Lenox Hill clinic for two hours once a week. He agreed, although that soon changed to one full day a week. He would come in at nine in the morning and leave at six. He did this for five years and quickly became a close friend and mentor.

I learned an extraordinary amount from Hans, all to the benefit of our patients, who began returning to normal lives following successful treatments that relieved their pain.

The number of back surgeries continues to rise. Today, in fact, back operations are by far the fastest-growing surgery in the country. There are now on the order of 400,000 back operations annually; 150,000 to 200,000 are spinal fusions. Additional studies have shown as many as half the operations are failures. A more measured, thoughtful approach than spine surgery could help patients suffering with back pain. But even many of the competing interventions, such as nerve blocks and nerve stimulation techniques, are bound to fail because they too are aimed at the wrong target.

The history of medicine is replete with examples of significant advances that were met with opposition, even ridicule, by the reigning authorities. Some were as sophisticated as the discovery of blood circulation, others as simple as the need for doctors to wash their hands. We can add to the list the fact that muscles, not spinal deformations, are the cause of most common back pain.

———————————————————————————————————————————————

This concludes the excerpts from Chapter 2 of my new book, End Back Pain Forever. The upcoming book (which can be found here) will cover what you have read so far and more, such as a more in-depth look at the role of stress in pain, the anatomy of the spine and muscles, tips about daily living, and therapeutic exercises that you can do at home. Thank you again for reading! #endbackpain

EP Global Communications Inc. (EPGL) Stock Research Links

EPGL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 92

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 147

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 143

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 303

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 185

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 292

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 96

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 146

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 239

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights on CDW's Market Position and P/E Ratio Analysis

Updated Category News Views 123

Analyzing CDW's Current Market Performance CDW Inc.'s current stock price stands at $164.29, reflecting a notable increase of 2.59% during the ongoing market session. Despite this uptick, shareholders might be concerned as the stock has experienced a decline of 6.53% over the past month and a more significant drop of 24.18% over the last year. With these figures, it...

Continue Reading
What the Recent Earnings Report Means for FactSet Research

Updated Category News Views 135

FactSet Research Exceeds Expectations in Q1 Performance FactSet Research Systems Inc. (NYSE: FDS) has reported first-quarter results that exceeded analyst expectations, showcasing strong performance in a competitive financial market. The company achieved first-quarter sales totaling $607.6 million, surpassing the anticipated $600.5 million, which reflects a commendable...

Continue Reading
Dime Community Bancshares Unveils Executive Transition Plans

Updated Category News Views 180

Dime Community Bancshares Executive Changes Dime Community Bancshares, Inc. (NASDAQ: DCOM) recently announced significant changes in its leadership team as part of a strategic succession plan. This initiative reflects the company’s commitment to fostering a robust executive structure and enhancing its operational growth. Leadership Transition Details As Dime prepares...

Continue Reading
Hygiene Products Industry on Track to Reach $14.62 Billion

Updated Category News Views 112

Overview of the Antiseptic Products Market The global antiseptic products market is projected to experience remarkable growth, reaching an estimated value of USD 10.85 billion in 2025, and anticipated to climb to USD 14.62 billion by 2032. This represents a compound annual growth rate (CAGR) of 4.35% during the period. As health-conscious consumers become increasingly...

Continue Reading
China's Enduring Commitment to Global Peace and Prosperity

Updated Category News Views 91

China's Historical Role in the UN The United Nations (UN) stands as a testament to humanity's resolve for peace, shaped significantly by historical events like the World Anti-Fascist War. This war saw the Allies, including China, rally against the Axis powers, fostering a crucial international alliance. Founded as a result of collective victories, the UN embodies the...

Continue Reading